Abarceo Pharma AB has identified VDAC1 as a key target in Type II diabetes, and is developing antibodies and small molecule inhibitors against the target as durable and disease-modifying treatments. Standard first-line therapy for Type...

INDICATION: Parkinson’s disease (PD); neurology; blindness Fruit fly studies suggest inhibiting ITPR, VDAC1, MCU, MIRO1 and/or MIRO2 could help treat PD, other neurodegenerative diseases and blindness. In a Drosophila model of PD, knockdown of ITPR...

Vidac Pharma Ltd. (Jerusalem, Israel) said 10% VDA-1102 ointment missed the primary endpoint of reducing the mean number of actinic keratosis (AK) lesions on the face or scalp combined from baseline to day 56 vs....

Since its acquisition two years ago by New WuXi Life Science Ltd. , WuXi NextCode Genomics Inc. has been busy building out its artificial intelligence (AI) capabilities and test driving them via its expanding network of...

BC Staff A new Israeli VC fund is leveraging a broad base of biopharma advisers to give its portfolio companies an advantage in development, partnering and commercialization activities. Israel Biotech Fund is raising its first...

Vidac Pharma (Jerusalem, Israel) raised $9 million in a series A financing led by new investor Israel Biotech Fund. Existing investors including Mivtach Shamir Holdings also participated. The company's VDA-1102 ointment is in a Phase...

Neurology INDICATION: Diabetic neuropathy; neuropathy Mouse studies suggest inhibiting VDAC1 could help treat diabetic neuropathy and Charcot-Marie-Tooth 1A (CMT1A) disease. In mouse models of diabetic neuropathy and CMT1A, a VDAC1 inhibitor tool compound increased nerve...